Longer spondyloarthritis disease duration ups risk of hypertension
A higher risk of hypertension correlates with the disease duration of spondyloarthritis (SpA), particularly in axial disease, suggests a recent study. Moreover, exposure to nonsteroidal anti-inflammatory drugs (NSAID) does not seem to contribute to the risk of hypertension.
Analysis was performed using data from 3,923 patients (median SpA disease duration, 5.1 years; interquartile range, 1.3–11.8 years). The main cardiovascular (CV)-related conditions assessed were as follows: hypertension (22.4 percent), ischaemic heart disease (2.6 percent), stroke (1.3 percent) and diabetes mellitus (5.5 percent).
Both univariable and multivariable analyses showed an association between hypertension and SpA disease duration (odds ratio [OR] for each 5-year increase in disease duration, 1.129, 95 percent CI, 1.072–1.189; p<0.001). Apart from SpA disease duration, factors such as age, male sex, current body mass index, ever steroid therapy and ever synthetic disease-modifying antirheumatic drug therapy, but not NSAID, were also associated with hypertension.
In addition, subgroup analysis revealed that patients with the axial-only SpA phenotype were at greatest risk of hypertension (OR, 1.202, 1.053–1.372), but not those with peripheral-only SpA (OR, 0.902, 0.760–1.070). Other CV conditions did not show any association with SpA disease duration.
The investigators used data from the COMOSPA study to assess the associations between SpA disease duration and CV-related conditions in univariable and multivariable logistic regression models. Adjusting for relevant confounders, each model examined one CV-related factor as dependent and “SpA disease duration” as predictor.
“SpA is associated with a number of CV comorbidities,” the investigators noted.